Table 2 32-week incidence of and comparative mRNA booster effectiveness against breakthrough COVID-19 and death or hospitalization with COVID-19 pneumonia following vaccination and booster in adults
Overall cohort (N = 1,703,189) | Average-risk populations (N = 110,485) | High-risk populations (N = 1,592,704) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
COVID-19 outcome by vaccination and booster | 32-week Risk (95% CI)a | Risk diff. (95% CI)a | NNVb (95% CI)a | 32-week Risk (95% CI)a | Risk diff. (95% CI)a | NNVb (95% CI)a | 32-week Risk (95% CI)a | Risk diff. (95% CI)a | NNVb (95% CI)a | |
Events per 10,000 persons | Events per 10,000 persons | Events per 10,000 persons | Events per 10,000 persons | Events per 10,000 persons | Events per 10,000 persons | |||||
Breakthrough COVID-19 (N = 22,848) | ||||||||||
Overall | 149.3 (147.3, 152.1) | - | - | 199.5 (184.1, 215.1) | - | - | 147.1 (143.9, 149.6) | - | - | |
mRNA-1273 ×3 | 137.5 (133.6, 140.9) | Ref. | Ref. | 188.7 (165.7, 217.5) | Ref. | Ref. | 134.7 (130.8, 138.6) | Ref. | Ref. | |
BNT162b2 ×3 | 161.5 (158.1, 165.0) | 23.9 (19.8, 29.9) | 415.5 (334.7, 505.3) | 210.1 (190.4, 229.4) | 21.4 (−12.7, 53.4) | 411.1 (−7,320.8, 4,913.9) | 159.2 (154.9, 162.4) | 24.5d (18.7, 29.4) | 414.2 (340.0, 534.7) | |
Death or hospitalization with COVID-19 pneumoniac (N = 1649) | ||||||||||
Overall | 10.9 (10.2, 11.8) | - | - | 1.4 (0.6, 2.6) | - | - | 11.5 (10.8, 12.4) | - | - | |
mRNA-1273 ×3 | 9.8 (8.8, 11.1) | Ref. | Ref. | 1.1 (0.1, 2.6) | Ref. | Ref. | 10.3 (9.5, 11.6) | Ref. | Ref. | |
BNT162b2 ×3 | 11.9 (12.9, 10.8) | 2.1 (0.6, 3.3) | 4,936.6 (3,028.8, 16,670.3) | 1.7 (0.4, 3.6) | 0.6 (−1.4, 2.7) | 7,110.7 (−87,369.5, 216,408.7) | 12.5 (11.7, 13.7) | 2.2d (0.9, 3.6) | 4,505.9 (2,674.5, 10,665.9) | |
